Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia.
You may also like
Physicians still remain at higher risk for burnout compared to other professionals
- February 24, 2019
The good news is that physicianRead more
A cut finite element method for elliptic bulk problems with embedded surfaces
- February 23, 2019
Burman, E; Hansbo, P; Larson, MG;Read more